Navigation Links
Tianyin Pharmaceutical Co., Inc. Announces First Quarter 2009 Financial Results

-- First Quarter 2009 Revenue Increased 33.4% to $9.6 Million and Net

Income Increased 10.9% to $1.8 Million -- First Quarter 2009 Gross Margins Improved 1090-Basis Point to 51% over

First Quarter 2008

-- Company Received Chinese SFDA Approval for Fuke Zhidai Tablets

CHENGDU, China, Nov. 11 /Xinhua-PRNewswire-FirstCall/ -- Tianyin Pharmaceutical Co., Inc., (NYSE: TPI), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced results for its first quarter 2009 ended September 30, 2008.

Revenue for the first quarter of 2009 increased 33.4% to approximately $9.6 million compared to approximately $7.2 million for the first quarter of 2008. The increase in revenues was primarily due to enhanced marketing efforts, expansion of current sales channels and broadened product portfolio.

Cost of goods sold for the first quarter was approximately $4.7 million, yielding a gross profit of $4.9 million and gross margins of 51%, compared to $2.9 million in gross profit and a gross margin of 40.1% during the first quarter of 2008. Thus, gross profits grew by 69.7% on a year-over-year basis. The increase in gross profit and improved margins were primarily attributable to the growth in revenue, the relatively stable price of raw materials and the management's focus on high margin products. The sales of Ginkgo Mihuan Oral Liquid and Arpu Shuangxin, which had comparatively higher gross margin, increased 340% and 31% respectively, compared to that for the same period in 2007.

Operating expenses for the three months ended September 30, 2008 were $2.7 million, up 155.4% compared to the same period in 2007. Selling, general and administration expenses for the period increased to approximately $2.6 million from $1 million in the first quarter of 2008. The increase in SG&A expenses was mainly the result of the Company's efforts to strengthen the marketing and sales activities to increase revenue, including increasing advertisement and promotion, and hiring more sales people. For the three months ended September 30, 2008, the number of employees in Tianyin's sales department increased by 206 employees, compared to the same period one year ago, resulting in a total of 720 sales people. Research and development expenses were $82,638 in the three months ended September 30, 2008, versus $27,451.

Operating income for the first quarter of 2009 totaled approximately $2.2 million, a 19.4% increase from the $1.8 million reported for the first quarter of 2008. Operating margins were 22.6% and 25.3% for the first quarter of 2009 and 2008, respectively. The decrease in the operating margin was due to increased spending on R&D and marketing to expand Tianyin's market presence.

For the first quarter of 2009, net income was $1.8 million, a 10.9% increase, compared to $1.5 million for the first quarter of 2008. Fully diluted earnings per share were $0.07 compared to $0.12 for the first quarter of 2009 and 2008 respectively, based up on 24.6 million and 12.8 million shares. The increase in net income was primarily due to increased sales with higher gross margin.

"We continued to experience strong year-over-year revenue and earning growth from our current portfolio of products combined with enhanced gross profit margins. We believe the results validate the plan management has been implementing to focus on products with high gross margins and increased sales and marketing efforts. We expect the benefits of these will continue into the future as well," Dr. Guoqing Jiang, Chief Executive Officer of Tianyin, commented.

Balance Sheet and Cash Flow

The Company had a current ratio of 6.4 to 1 and $12.4 million in cash and cash equivalents on September 30, 2008. The Company had Stockholders' Equity of $35.1 million, with total assets of $38.5 million versus total liabilities of $3.4 million. For the first three months of fiscal year 2009, the Company generated $0.5 million in cash from operations versus $1 million for the same period in 2008.

Business Development

Tianyin has received approval from the Chinese State Food and Drug Administration (SFDA) to produce Laonian Kechuan Tablets in the dosage form of 0.25 gram/tablet (SFDA approval number Z20083360) and Fuke Zhidai Tablets in the dosage form of 0.4 gram/tablet (SFDA approval number Z20083375). Laonian Kechuan Tablets is a TCM drug that effectively treats asthma in people aged 60 or above. Fuke Zhidai Tablets is a TCM drug used to treat abnormal leucorrhea, which is caused by chronic cervicitis, endometritis and endocolpitis. The Company plans to launch Laonian Kechuan Tablets and Fuke Zhidai Tablets in the domestic market and begin recording revenue in November 2008 and December 2008, respectively. The Company launched the production of Azithromycin Dispersible Tablets in August 2008 and is due to market the new product in October 2008. Azithromycin is highly effective in treating upper and lower respiratory tract infections and other bacterial infections in the skin and reproductive system. Tianyin received approval from the Chinese State Food and Drug Administration (SFDA) to produce Azithromycin Dispersible Tablets in December 28, 2007.

Tianyin continues to invest in information systems and post-marketing studies and monitoring to improve efficiency. The Company is also making progress constructing the plant they started building in the end of April 2008. Also, Tianyin continues to evaluate acquisition opportunities which will complement the existing product and manufacturing lines, as well as provide accretive earnings growth.

Tianyin's common stock began trading on the NYSE Alternext U.S. (formerly known as the American Stock Exchange) under the ticker "TPI" at market open on Wednesday, October 1, 2008. In addition, the Company's board of directors approved a $3 million stock repurchase program on October 28, 2008.

"In the first quarter of fiscal year 2009, our organic growth from existing core products and new products launched in fiscal year 2008 demonstrates the success of our growth strategy. We received two approvals from the Chinese SFDA to produce Laonian Kechuan Tablets and Fuke Zhidai Tablets. We plan to launch these two drugs before the end of 2008 and we are optimistic that these new drugs will further improve our profitability and be additional growth contributors to our top-line and bottom-line numbers. We will continue to focus on broadening our product portfolio, increasing our sales and marketing activities, and further expanding our distribution network. Our extensive market research provides evidence that we are well positioned in the Chinese pharmaceutical industry, the benefit of which will continue to support our revenue and net income growth throughout fiscal 2009 and beyond," concluded Dr. Jiang.

Conference Call

The Company will host a conference call to discuss the 2009 first quarter financial results on Tuesday, November 11, 2008 at 8:30 a.m. EST. Interested participants should call 800-762-8795 within the United States, or US +1-480- 629-9031 if calling internationally. The conference ID is 3940851. It is advisable to dial in approximately 5-10 minutes prior to 8:30 a.m. EST. If you are unable to participate in the call at the scheduled time, a playback will be available on Tuesday, November 11, 2008 at 11:30 a.m. ET through Thursday, November 27, 2008 at 11:59 p.m. ET. To listen to the playback, please call 800-406-7325 from within the United States, or US +1 303-590-3030 internationally. Please use pass code 3940851 for the replay.

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 33 modernized TCMs and 5 generic western medicines in the market, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance Program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 47 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 720 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,365 employees. Tianyin achieved revenue of approximately $33.5 million and net income of approximately $6 million in FY2008 ending June 30, 2008. For more information about Tianyin Pharmaceuticals, please visit .

Safe Harbor Statement

This Press Release contains or may contain forward looking statements and information that are based upon beliefs of and information currently available to the Company's management as well as estimates and assumptions made by the Company's management. When used herein the words "anticipate", "believe", "estimate", "expect", "future", "intend", "plan" and similar expressions as they relate to the Company or the Company's management identify forward looking statements. These statements involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, intended or planned.


Consolidated Balance Sheets


September 30, June 30,

2008 2008



Current assets:

Cash and cash equivalents $12,417,925 $12,057,150

Accounts receivable, net of

allowance for doubtful

accounts of $90,311

and $90,064 at September 30,

2008 and June 30,

2008, respectively 4,560,718 4,460,406

Inventory 4,584,781 3,555,691

Other receivables 712,120 371,815

Other current assets 94,317 247,139

Total current assets: 22,369,861 20,692,201

Property and equipment, net: 5,695,589 5,758,966

Intangibles, net: 10,471,414 10,307,754

Total assets: $38,536,864 $36,758,921

Liabilities and stockholders' equity:

Current liabilities:

Accounts payable and accrued expenses $1,280,592 $1,337,682

Short-term bank loans 1,397,165 1,393,345

VAT taxes payable 262,079 277,090

Income tax payable 358,629 341,214

Payroll taxes payable 17,354 39,939

Dividend payable -- 378,545

Other current liabilities 113,866 142,733

Total current liabilities: 3,429,685 3,910,548

Total liabilities: 3,429,685 3,910,548

Stockholders' equity:

Common stock, $0.001 par value,

50,000,000 shares authorized,

15,465,563 and 14,738,450

shares issued and outstanding at

September 30, 2008 and June 30, 2008 15,466 14,739

Common stock dividend distributable 226 --

Series A convertible preferred

stock, $0.001 par value,8,893,750

9,384,375 shares issued and

outstanding at September 30, 2008

and June 30, 2008 8,894 9,384

Additional paid-in capital 18,741,688 18,002,439

Statutory reserve 1,584,154 1,380,806

Retained earnings 12,189,443 10,963,131

Accumulated other comprehensive income 2,567,308 2,477,874

Total stockholders' equity: 35,107,179 32,848,373

Total liabilities and

stockholders' equity: $38,536,864 $36,758,921

Consolidated Statements of Operations and Comprehensive Income


For the Three Months Ended

September 30,

2008 2007

Sales: $9,561,940 $7,169,493

Cost of goods sold: 4,682,624 4,293,829

Gross profit: 4,879,316 2,875,664

Operating expenses:

Selling, general and administrative 2,633,361 1,036,480

Research and development 82,638 27,451

Total operating expenses: 2,715,999 1,063,931

Income from operations: 2,163,317 1,811,733

Other income (expenses):

Other income 14,245 --

Interest expense (27,720) (34,703)

Total other income (expenses): (13,475) (34,703)

Income before provision for income tax: 2,149,842 1,777,030

Provision for income tax: 358,849 265,074

Net income: 1,790,993 1,511,956

Other comprehensive income:

Foreign currency translation adjustment 89,434 183,851

Comprehensive income: $1,880,427 $1,695,807

Basic earnings per share: $0.09 $0.12

Diluted earnings per share: $0.07 $0.12

Weighted average number of common shares


Basic 15,357,818 12,790,800

Diluted 24,558,625 12,790,800

Consolidated Statements of Cash Flows


For the Three Months Ended

September 30,

2008 2007

Cash flows from operating activities:

Net Income $1,790,993 $1,511,956

Adjustments to reconcile net income to

net cash provided by (used in) operating


Depreciation and amortization 119,399 81,486

Changes in current assets and

current liabilities:

Accounts receivable (88,138) 7,982

Inventory (1,019,969) 285,546

Other receivables (339,566) (159,635)

Advances to suppliers -- (397,200)

Other current assets 152,822 --

Accounts payable and accrued expenses (60,470) (277,424)

VAT taxes payable (15,780) (40,499)

Income tax payable 16,489 (42,565)

Payroll taxes payable (22,708) --

Other current liabilities (29,277) 77,928

Total adjustments: (1,287,198) (464,381)

Net cash provided by

operating activities: 503,795 1,047,575

Cash flows from investing activities:

Additions to property and equipment -- (713)

Additions to intangibles (175,668) --

Net cash used in investing

activities: (175,668) (713)

Cash flows from financing activities:

Additional paid-in capital -- 8,000

Issuance of preferred stock -- 140,207

Repayment of short-term bank loans -- (794,760)

Repayment of long-term bank loans -- (120,541)

Net cash provided by (used

in) financing activities: -- (767,094)

Effect of foreign currency translation

on cash: 32,648 11,007

Net increase in cash and cash

equivalents: 360,775 290,775

Cash and cash equivalents - beginning: 12,057,150 624,390

Cash and cash equivalents - ending: $12,417,925 $915,165

For more information, please contact:

For the Company:

Allen Tang, Ph.D., MBA

Assistant to the CEO

Tel: +86-158-212-25642 (China)



HC International, Inc.

Alan Sheinwald

Tel: +1-914-669-0222 (U.S.)


SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Tianyin Pharmaceutical Co., Inc. to Present at Rodman & Renshaw Annual Global Investment Conference in New York City on November 11, 2008 at 12:00 p.m. EST
2. Tianyin Pharmaceutical to Present at the Brean Murray All-Cap All-China Conference in New York City on May 20, 2008 at 10:15 a.m. EDT
3. Tianyin Pharmaceutical Announces SFDA Approval to Market Azithromycin Dispersible Tablets
4. Tianyin Pharmaceutical Appoints Three New Independent Board Members
5. Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results
6. Tianyin Pharmaceutical, Inc. to Host 2008 Second Quarter Earnings Conference Call on Thursday, February 14, 2008 at 4:15 p.m. EST
7. Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
8. Stem Cell Sciences Licenses Stem Cell Technology to Leading Provider of Genetically Modified Models for Pharmaceutical Research
9. Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
10. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
11. Shengtai Pharmaceutical Schedules 2009 First Quarter Financial Results and Conference Call
Post Your Comments:
(Date:11/27/2015)... , Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc (NYSE: ... today that it has closed the sale of its ... Guerbet (GBT- NYSE Euronext) in a transaction valued at ... manufacturing facilities and a total of approximately 1,000 employees ... St. Louis area. This entire ...
(Date:11/26/2015)... England , November 26, 2015 ... medical device company specializing in imaging technologies, announced today that ... Commission as part of the Horizon 2020 European Union Framework ... out a large-scale clinical trial in breast cancer. ... , --> --> ...
(Date:11/25/2015)... 25, 2015 Studies reveal the ... plaque and pave the way for more effective treatment for ...     --> --> ... health problems in cats, yet relatively little was understood about ... studies have been conducted by researchers from the WALTHAM Centre ...
(Date:11/25/2015)... ... 25, 2015 , ... A long-standing partnership between the Academy ... been formalized with the signing of a Memorandum of Understanding. , AMA Executive ... Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at AMA Headquarters ...
Breaking Biology Technology:
(Date:11/2/2015)... MENLO PARK, Calif. , Nov. 2, 2015 /PRNewswire/ ... to $9 million to provide preclinical development services to ... Under the contract, SRI will provide scientific expertise, modern ... a wide variety of preclinical pharmacology and toxicology studies ... --> --> The PREVENT Cancer Drug ...
(Date:10/29/2015)... RESTON, Va. , Oct. 29, 2015 ... announced today that it has released a new version ... Daon customers in North America ... gains. IdentityX v4.0 also includes a FIDO UAF ... customers are already preparing to activate FIDO features. These ...
(Date:10/29/2015)... 29, 2015 NXTD ) ... focused on the growing mobile commerce market and ... StackCommerce, a leading marketplace to discover and buy ... smart wallet on StackSocial for this holiday season. ... the "Company"), a biometric authentication company focused on ...
Breaking Biology News(10 mins):